Biblio

Export 5 results:
Author Title Type [ Year(Desc)]
Filters: Author is Espay, Alberto J  [Clear All Filters]
2021
A. J. Espay, Sturchio, A., Schneider, L. S., and Ezzat, K., “Soluble Amyloid-β Consumption in Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. 4, pp. 1403-1415, 2021.
2022
A. Sturchio, Dwivedi, A. K., Malm, T., Wood, M. J. A., Cilia, R., Sharma, J. S., Hill, E. J., Schneider, L. S., Graff-Radford, N. R., Mori, H., Nübling, G., Andaloussi, S. El, Svenningsson, P., Ezzat, K., and Espay, A. J., “High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.”, J Alzheimers Dis, vol. 90, no. 1, pp. 333-348, 2022.
2023
K. P. Kepp, Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., Vissel, B., and Espay, A. J., “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
M. Pacheco Pachado, Casas, A. I., Elbatreek, M. H., Nogales, C., Guney, E., Espay, A. J., and Schmidt, H. H. H. W., “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
2024
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.